Press releaseBusiness Wire
Foghorn Therapeutics
FHTX · NASDAQ
$2.01+$0.14 (+7.49%)TodayMarket closed ·
Prev close $1.87
Latest news
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
- NewsAvi Kapoor
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
- NewsVandana Singh
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
- NewsAvi Kapoor
Dow Falls Over 200 Points; Micron Earnings Top Views
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
- Press releaseGlobe Newswire
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
- Press releaseGlobe Newswire
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director
- Press releaseGlobe Newswire
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Press releaseGlobe Newswire
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
- Press releaseGlobe Newswire
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- Press releaseGlobe Newswire
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Press releaseGlobe Newswire
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Press releaseGlobe Newswire
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
- Press releasePRNewswire
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
- Press releasePRNewswire
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
- Press releasePRNewswire
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering
- Press releasePRNewswire
Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform
- Press releasePRNewswire
Ted Myles Joins Cellarity as Chief Executive Officer
- Press releasePRNewswire
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics
- Press releasePRNewswire
Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare
- Press releasePRNewswire
Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
- NewsAvi Kapoor
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
- Press releasePRNewswire
Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science
- Press releasePRNewswire
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health
- Press releasePRNewswire
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation
- NewsHenry Khederian
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
- Press releasePRNewswire
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies
- Press releasePRNewswire
Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer
- Press releasePRNewswire
Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner
- Press releasePRNewswire
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio
- Press releasePRNewswire
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
- Press releasePRNewswire
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
- NewsAvi Kapoor
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.